Accéder au contenu
Merck

Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells.

Scientific reports (2019-10-04)
H Christian Eberl, Thilo Werner, Friedrich B Reinhard, Stephanie Lehmann, Douglas Thomson, Peiling Chen, Cunyu Zhang, Christina Rau, Marcel Muelbaier, Gerard Drewes, David Drewry, Marcus Bantscheff
RÉSUMÉ

Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues. These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition studies in combination with quantitative mass spectrometry. We present improved bead matrices that capture more than 350 protein kinases and 15 lipid kinases from human cell lysates, respectively. A multiplexing strategy is suggested that enables determination of apparent dissociation constants in a single mass spectrometry experiment. Miniaturization of the procedure enabled determining the target selectivity of the clinical BCR-ABL inhibitor dasatinib in peripheral blood mononuclear cell (PBMC) lysates from individual donors. Profiling of a set of Jak kinase inhibitors revealed kinase off-targets from nearly all kinase families underpinning the need to profile kinase inhibitors against the kinome. Potently bound off-targets of clinical inhibitors suggest polypharmacology, e.g. through MRCK alpha and beta, which bind to decernotinib with nanomolar affinity.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-JAK1 Antibody, clone 73, clone 73, from mouse